Commercialization agreement for Nufymco biosimilar Zydus Lifesciences Global FZE, a subsidiary of Zydus, has entered into an agreement with Bioeq to introduce Nufymco to the US market. Nufymco is an interchangeable biosimilar of Lucentis (Ranibizumab), a Vascular Endothelial Growth Factor (VEGF) inhibitor specialized for ophthalmology. This move follows the recent approval by the US Food and Drug Administration (FDA), which grants Nufymco interchangeable status, allowing it to be substituted for the reference product in clinical settings.
Defined roles and strategic objectives Under the partnership terms, Bioeq is responsible for the entire lifecycle of the product, including development, manufacturing, regulatory registration, and supply. In contrast, Zydus will leverage its extensive distribution network and marketing expertise to lead the commercialization efforts across the United States. The shared goal is to optimize resources to provide patients with high-quality ophthalmic care at more affordable prices while expanding Zydus’ biosimilar portfolio in one of the world’s most regulated markets.
Expanding North American operations The collaboration with Bioeq marks another step in Zydus’ expansion strategy within the region. Earlier this month, the company also secured an agreement with Zormycon to supply a biosimilar of Keytruda in the US and Canada. These efforts reflect the firm’s commitment to enhancing public access to advanced therapies through business model innovation and integrated manufacturing partnerships.
Source: https://www.pharmaceutical-technology.com/news/zydus-bioeq-commercialisation-nufymco/?cf-view